Related Experiment Video
Updated: Feb 4, 2026
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
Real-life effectiveness of MP-AzeFlu in Irish patients with persistent allergic rhinitis, assessed by visual analogue
Ranbir Kaulsay1, Duc Tung Nguyen2, Hans Christian Kuhl2
1Bon Secours Consultant Private Clinic, Beacon ENT and Allergy Clinic at Beacon Hospital, Dublin, Ireland.
Introduction:
Most allergic rhinitis (AR) patients have moderate-to-severe, persistent disease. Meda Pharma's AzeFlu (MP-AzeFlu) combines intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel formulation in a single device to treat AR. This prospective, noninterventional study sought to assess the effectiveness of MP-AzeFlu (one spray/nostril twice daily; 548 µg AZE/200 µg FP daily dose) in relieving AR symptom severity.
Methods:
A visual analogue scale (VAS) was used prior to MP-AzeFlu treatment on days 0, 1, 3, 7, 14, 21, 28, 35, and 42 by 53 persistent AR (PER) patients seen in routine clinical practice in Ireland. An endoscopy was performed on days 0 and 28, and symptoms of edema, discharge, and redness were scored on a three-point scale (for both nostrils).
Results:
Patients using MP-AzeFlu experienced rapid VAS score reduction from 73.4 mm (standard deviation [SD], 20.3) at Day 0 to 31.5 mm (SD, 25.0) at day 28 (P < 0.0001) to 28.1 mm (SD, 24.1) at day 42 (P < 0.0001), a 45.3-mm reduction. On average, patients achieved a clinically relevant VAS score cutoff of 50 mm before Day 7. Total endoscopy score decreased from 7.5 mm (SD, 3.1) at baseline to 3.5 mm (SD, 2.5) at Day 28. The incidence of severe edema on endoscopy decreased from 53.1% at baseline to 3.8% at Day 28. A similar reduction in the incidence of thick/mucousy discharge (from 28.3% to 4.8%) and severe redness (from 34.9% to 0%) was also observed.
Conclusions:
MP-AzeFlu provided effective, rapid control of PER as assessed by VAS in a real-world clinical setting in Ireland. Symptom improvement was observed at Day 1, sustained for 42 days, and associated with improved mucosal appearance after 28 days. These results confirm the safety of MP-AzeFlu and exceed the efficacy demonstrated in phase 3 clinical studies for controlling AR in PER patients.
Insights
Meda Pharma
Area of Science:
- Allergy and Immunology
- Pharmacology
- Otolaryngology
Background:
- Most patients with allergic rhinitis (AR) experience moderate-to-severe persistent symptoms.
- Intranasal azelastine hydrochloride (AZE) and fluticasone propionate (FP) combination therapy in a single device (MP-AzeFlu) offers a novel treatment approach for AR.
Purpose of the Study:
- To assess the real-world effectiveness of MP-AzeFlu in alleviating symptom severity in patients with persistent allergic rhinitis (PER).
Main Methods:
- Prospective, noninterventional study involving 53 PER patients in Ireland.
- Symptoms were evaluated using a visual analogue scale (VAS) and nasal endoscopy over 42 days.
- MP-AzeFlu was administered as one spray per nostril twice daily (548 µg AZE/200 µg FP daily).
Main Results:
- MP-AzeFlu significantly reduced VAS scores from 73.4 mm at baseline to 31.5 mm at day 28 and 28.1 mm at day 42 (P < 0.0001).
- Clinically relevant symptom relief (VAS ≤ 50 mm) was achieved before day 7 for most patients.
- Nasal endoscopy showed decreased edema, discharge, and redness, indicating improved mucosal appearance.
Conclusions:
- MP-AzeFlu provides rapid and effective symptom control for PER patients in a real-world clinical setting.
- Symptom improvement was sustained for 42 days, with enhanced nasal mucosal appearance.
- The study confirms the safety and efficacy of MP-AzeFlu, exceeding findings from previous phase 3 trials.
Related Concept Videos
02:06Allergic Reactions
02:42Half-life of a Reaction
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
01:23Characteristics of Life
02:39The Angiosperm Life Cycle
02:41pH Scale